Table 4. Overall meta-analysis of the association between the -607 polymorphism (rs1946518) and risk of hepatocellular carcinoma.
| Genotype comparison and genetic model | OR [95% CI] | Z (P value) | Heterogeneity of study design | Analysis model | ||
|---|---|---|---|---|---|---|
| χ2 | df (P value) | I2 (%) | ||||
| IL18 -607 (rs1946518) in total population from 7 case-control studies (1,262 cases and 1,696 controls) | ||||||
| Allelic (C-allele vs. A-allele) | 0.99 [0.81, 1.22] | 0.08 (0.94) | 20.67 | 6 (0.002) | 71 | Random |
| Recessive (CC vs. AC + AA) | 1.02 [0.86, 1.21] | 0.22 (0.83) | 10.14 | 6 (0.12) | 41 | Fixed |
| Dominant (AA vs. AC + CC) | 1.02 [0.72, 1.45] | 0.09 (0.93) | 21.67 | 6 (0.001) | 72 | Random |
| Homozygous (CC vs. AA) | 0.94 [0.59, 1.49] | 0.27 (0.79) | 23.91 | 6 (<0.001) | 75 | Random |
| Heterozygous (AC vs. AA) | 1.01 [0.74, 1.39] | 0.08 (0.93) | 15.91 | 6 (0.01) | 62 | Random |
| IL18 -607 (rs1946518) in Asian population from 6 case-control studies (1,150 cases and 1,494 controls) | ||||||
| Allelic (C-allele vs. A-allele) | 1.06 [0.87, 1.28] | 0.59 (0.55) | 13.51 | 5 (0.02) | 63 | Random |
| Recessive (CC vs. AC + AA) | 1.08 [0.90, 1.30] | 0.79 (0.43) | 7.55 | 5 (0.18) | 34 | Fixed |
| Dominant (AA vs. AC + CC) | 0.88 [0.66, 1.18] | 0.86 (0.39) | 11.74 | 5 (0.04) | 57 | Random |
| Homozygous (CC vs. AA) | 1.12 [0.75, 1.68] | 0.56 (0.57) | 13.89 | 5 (0.02) | 64 | Random |
| Heterozygous (AC vs. AA) | 1.17 [0.97, 1.40] | 1.62 (0.10) | 7.86 | 5 (0.16) | 36 | Fixed |
| IL18 -607 (rs1946518) in Chinese population from 4 case-control studies (832 cases and 1,151 controls) | ||||||
| Allelic (C-allele vs. A-allele) | 0.99 [0.79, 1.23] | 0.10 (0.92) | 8.23 | 3 (0.04) | 64 | Random |
| Recessive (CC vs. AC + AA) | 1.01 [0.82, 1.25] | 0.12 (0.90) | 4.19 | 3 (0.24) | 28 | Fixed |
| Dominant (AA vs. AC + CC) | 0.99 [0.70, 1.40] | 0.05 (0.96) | 7.39 | 3 (0.06) | 59 | Random |
| Homozygous (CC vs. AA) | 0.98 [0.62, 1.54] | 0.09 (0.93) | 8.46 | 3 (0.04) | 65 | Random |
| Heterozygous (AC vs. AA) | 1.05 [0.85, 1.31] | 0.47 (0.64) | 4.92 | 3 (0.18) | 39 | Fixed |
| IL18 -607 (rs1946518) in patients with hepatitis B virus-related HCC from 5 case-control studies (922 cases and 1194 controls) | ||||||
| Allelic (C-allele vs. A-allele) | 1.02 [0.80, 1.28] | 0.13 (0.89) | 12.20 | 4 (0.02) | 67 | Random |
| Recessive (CC vs. AC + AA) | 1.04 [0.84, 1.28] | 0.37 (0.71) | 6.97 | 4 (0.14) | 43 | Fixed |
| Dominant (AA vs. AC + CC) | 0.94 [0.67, 1.33] | 0.34 (0.73) | 10.31 | 4 (0.04) | 61 | Random |
| Homozygous (CC vs. AA) | 1.03 [0.63, 1.66] | 0.10 (0.92) | 12.29 | 4 (0.02) | 67 | Random |
| Heterozygous (AC vs. AA) | 1.09 [0.81, 1.46] | 0.57 (0.57) | 6.81 | 4 (0.15) | 41 | Fixed |
HCC, hepatocellular carcinoma; IL18, interleukin-18; OR, odds ratio; 95% CI, 95% confidence interval.